Disease response
| Response . | TN CLL/SLL (n = 20) . | R/R CLL/SLL (n = 25) . | R/R FL (n = 36) . |
|---|---|---|---|
| ORR | 20 (100) | 23 (92) | 26 (72) |
| Best response | |||
| CR | 6 (30) | 7 (28) | 14 (39) |
| PR | 14 (70) | 16 (64) | 12 (33) |
| Stable disease | 0 | 2 (8) | 6 (17) |
| PD | 0 | 0 | 4 (11) |
| ORR for del(17p)/p53 mutation (n = 16) | 6 of 6 (100) | 8 of 10 (80) | — |
| Follow-up period, mo | |||
| Median | 29 | 29 | 20 |
| Range | 14-35 | 8-37 | 2-37 |
| Response . | TN CLL/SLL (n = 20) . | R/R CLL/SLL (n = 25) . | R/R FL (n = 36) . |
|---|---|---|---|
| ORR | 20 (100) | 23 (92) | 26 (72) |
| Best response | |||
| CR | 6 (30) | 7 (28) | 14 (39) |
| PR | 14 (70) | 16 (64) | 12 (33) |
| Stable disease | 0 | 2 (8) | 6 (17) |
| PD | 0 | 0 | 4 (11) |
| ORR for del(17p)/p53 mutation (n = 16) | 6 of 6 (100) | 8 of 10 (80) | — |
| Follow-up period, mo | |||
| Median | 29 | 29 | 20 |
| Range | 14-35 | 8-37 | 2-37 |
Values are n (%) except as noted.
PR, partial response.